Rosalie Scholtes

5PUBLICATIONS
13CO-AUTHORS
Molecular targetsPharmacogenomicsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Feb 26, 2025
Kidney hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in diabetes: physiology and clinical implications.

David León-Jiménez, Vikas S Sridhar, Manuel López-Mendoza

|Sep 12, 2022
Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial.

Rosalie A Scholtes, Charlotte M Mosterd, Anne C Hesp

|Apr 28, 2022
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.

Taha Sen, Rosalie Scholtes, Peter J Greasley

|Nov 20, 2019
The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis.

Rosalie A Scholtes, Daniël H van Raalte, Ricardo Correa-Rotter

|Mar 08, 2019
Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?

Rosalie A Scholtes, Michaël J B van Baar, Yuliya Lytvyn

Pageof 1

Frequent Collaborators

3 joint publications

Hiddo J L Heerspink

2 joint publications

Petter Bjornstad

2 joint publications

Daniël H van Raalte

1 joint publications

Michaël J B van Baar